Tag: 200-300

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Formula: C6H5Br2NO The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein R4 = independently H, halo, alkyl, (un)substituted NH2, etc.; A2 = substituted Ph, pyridyl, or pyrimidinyl; A5 = substituted heterocyclyl] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Formula: C6H5Br2NO

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Formula: C6H5Br2NO

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 7, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Application of 25813-24-5 The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Application of 25813-24-5

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On August 6, 2014, Xiao, Dengming; Xu, Xinhe; Liu, Xijie; Hu, Yuandong; Yu, Honghao; Liu, Zhihua; Peng, Yong; Sun, Yinghui; Luo, Hong; Kong, Fansheng; Han, Yongxin; Sun, Jian published a patent.Safety of 3,5-Dibromo-4-methoxypyridine The title of the patent was Preparation of substituted 2-aminopyridine derivatives as protein kinase inhibitors. And the patent contained the following:

The present invention discloses substituted 2-aminopyridine derivatives I [wherein A1 = H, substituted aryl, aryloxymethyl, etc.; A2 = substituted Ph, pyridyl, pyrimidinyl, or pyrazolyl; A3 = H, arylamino, substituted heteroaryl, etc.; A5 = substituted heterocyclyl; with the proviso that at least one of A1 or A3 is H] or pharmaceutically acceptable salts thereof as inhibitors of protein kinase, specifically anaplastic lymphoma kinase (ALK), for treating non-small-cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroma, nasopharyngeal carcinoma, breast cancer, colorectal cancer, diffuse large B cell lymphoma, systemic histiocytosis, and neuroblastoma. For example, II was prepared in a multi-step synthesis, which showed inhibitory activity with IC50 of 9.8 nM against ALK. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Safety of 3,5-Dibromo-4-methoxypyridine

The Article related to preparation aminopyridine alk inhibitor treatment cancer human, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 3,5-Dibromo-4-methoxypyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On March 15, 2018, Chen, Xuxing; Geng, Meiyu; Jiang, Lei; Chen, Yi; Cao, Jianhua; Jiang, Qingyun; Shen, Qianqian; Ding, Jian; Yao, Yucai; Zhao, Zhao; Xiong, Yuanfang published a patent.Safety of 4-Bromo-2-isopropylpyridine The title of the patent was Pyrido five-element aromatic ring compound, preparation method therefor and use thereof. And the patent contained the following:

The present invention provides a pyrido five-element aromatic ring compound (e.g., I), and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Safety of 4-Bromo-2-isopropylpyridine

The Article related to pyridoarom ezh inhibitor antitumor autoimmune preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 4-Bromo-2-isopropylpyridine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 30, 2021, Zhou, Enxing; Liu, Yuan; Wang, Hanping; Wang, Jing; Shao, Ning; Wu, Guanglong published a patent.Product Details of 908267-63-0 The title of the patent was Preparation of heteroaromatics and their methods for inhibiting casein kinases. And the patent contained the following:

The disclosure provides methods for inhibiting CK1 delta or CK1 epsilon activity, comprising administering an effective amount of the compound of formula I, or a pharmaceutically acceptable salt thereof. Compounds of formula I wherein Ar1 is (un)substituted aryl; X1, X2 and X3 are independently C and N; R7 is absent and CN; ring A is absent, X1:CR2 and R3X1:CR2, 4- to 7-membered cycloalkyl, heterocycloalkyl, etc.; R2 is NH2, CN, carboxy, azido, etc.; R3 is halo and CN; ring B is absent, X2CR5, R6X2CH and R6X2CR5, 4- to 7-membered cycloalkyl, etc.; R5 is CO2-C1-6 alkyl, COR10, azido, amido, etc.; R10 is 4- to 7-membered cycloalkyl, heterocycloalkyl and 5- to 6-membered heteroaryl; R6 is C1-6 alkyl, azido, amido, aryl, etc.; dashed bonds are single and double bonds; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their casein kinase inhibitory activity. From the assay, it was determined that compound II exhibited 7.9 nM towards CK1δ. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Product Details of 908267-63-0

The Article related to heteroaromatic preparation casein kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Product Details of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On April 23, 1997, Onodera, Akira; Ninomiya, Hidetaka; Ohya, Hidenobu; Ishibashi, Daisuke; Komamura, Tawara; Katoh, Katsunori; Tanaka, Tatsuo; Morimoto, Hitoshi published a patent.Computed Properties of 28489-43-2 The title of the patent was Azomethine dyes and their use in ink-jet recording inks. And the patent contained the following:

A recording method comprises the step of ejecting an ink-jet recording ink on a receptor using an ink-jet printer, the ink comprising a dye represented by the formula I [R1, R2 = H, halogen, NH2, organic group; X = OH, NR3R4; R3, R4 = H, hydrocarbyl, heterocyclyl, or R1R3 or R3R4 form a ring; Y1, Y2 = N, CR; R = H, alkyl, acylamino; Y1 or Y2 = N; Z completes an (un)substituted 5- or 6-membered ring, which may bear another condensed ring; R2 or a substituent on Z has Hammett σp -0.3 to +1.0]. Thus, II was prepared in a 9-step synthesis from 6-methyl-2-pyridinamine and 5-tert-butyl-2-hydrazino-6H-1,3,4-thiadiazine. An ink with good color tone and storage stability was prepared from a I 3, H(OCH2CH2)2OH 10, Bu(OCH2CH2)3OH 7, PrOH 3, and H2O 77%. The experimental process involved the reaction of N,N-DIethyl-6-methyl-5-nitro-2-pyridinamine(cas: 28489-43-2).Computed Properties of 28489-43-2

The Article related to azomethine dye jet printing ink, pyrazolotriazole azomethine dye, aminopyridine azomethine dye, Dyes, Organic Pigments, Fluorescent Brighteners, and Photographic Sensitizers: Azo Dyes and Pigments and other aspects.Computed Properties of 28489-43-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On December 27, 2007, Arnold, James; Berg, Stefan; Chessari, Gianni; Congreve, Miles; Edwards, Phil; Holenz, Joerg; Kers, Annika; Kolmodin, Karin; Murray, Christopher; Patel, Sahil; Rakos, Laszlo; Rotticci, Didier; Sylvester, Mark; Oehberg, Liselotte published a patent.Computed Properties of 908267-63-0 The title of the patent was Substituted isoindoles as BACE inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cognitive impairment, Alzheimers disease, neurodegeneration and dementia. And the patent contained the following:

This invention relates to compounds having the structural formula I and to their pharmaceutically acceptable salt, compositions and methods of use. These compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer disease, neurodegeneration and dementia. Compounds of formula I wherein R1 is H, NO2, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl;, CONH-C1-6 alkyl, etc.; R2 is Me, (un)substituted C0-3 alkyl-C3-6 cycloalkyl, NO2, CN, substituted C2-4 alkenyl, etc.; R3 is H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-6 cycloalkyl, etc.; m is 0, 1, 2, and 3; and their pharmaceutically acceptable salts, solvates, salts of solvates thereof are claimed. Example compound II•TFA was prepared by Suzuki cross-coupling of [3-(3-bromo-4-hydroxyphenyl)-3-(4-methoxyphenyl)-3H-isoindol-1-yl]carbamic acid tert-Bu ester with 3-methoxyphenylboronic acid; the resulting [3-(6-hydroxy-3′-methoxybiphenyl-3-yl)-3-(4-methoxyphenyl)-3H-isoindol-1-yl]carbamic acid tert-Bu ester underwent hydrolysis to give compound II•TFA. All the invention compounds were evaluated for their BACE inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of 67 nM. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Computed Properties of 908267-63-0

The Article related to substituted isoindole preparation bace inhibitor, treatment alzheimer disease neurodegeneration dementia cognitive impairment isoindole preparation, Heterocyclic Compounds (One Hetero Atom): Indoles, Indolizines, Carbazoles, and Other Arenopyrroles and other aspects.Computed Properties of 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Yi, Xiao; Chen, Jing; Xu, Xiuling; Ma, Yongmin published an article in 2017, the title of the article was Solvent and substituent effects on the conversion of 4-methoxypyridines to N-methyl-4-pyridones.Formula: C6H5Br2NO And the article contains the following content:

In the reaction of 4-methoxypyridine derivatives with alkyl iodides in the presence or absence of solvent, not only the pyridinium ions but also the related 1-methylpyridones are produced. The presence of solvent favors the formation of the 1-methylpyridone. Electron withdrawing groups on the pyridine ring also favor this conversion. A possible mechanism is presented. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Formula: C6H5Br2NO

The Article related to solvent substituent effect methoxypyridine derivative alkyl iodide pyridone, Physical Organic Chemistry: Addition, Elimination, and Substitution Reactions and other aspects.Formula: C6H5Br2NO

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On February 5, 2004, Kwan, Tricia Ann; Lagreca, Susan Deborah; Lippa, Blaise Scott; Morris, Joel; Wessel, Matthew David published a patent.Formula: C8H10BrN The title of the patent was Preparation of isothiazole derivatives as anticancer agents. And the patent contained the following:

The title compounds I [X = O or S; R1 = (substituted)heterocyclic aromatic ring; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, etc.] were prepared Compounds I are useful as as anticancer agents (no data). Thus, reaction of 3-methanesulfonyl-5-(pyridin-4-ylamino)-isothiazole-4-carboxylic acid amide (preparation given) with (4-chlorophenyl)-methanethiol yielded compound II. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Formula: C8H10BrN

The Article related to isothiazole derivative preparation anticancer, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Formula: C8H10BrN

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

On September 30, 2021, Zhou, Enxing; Liu, Yuan; Wang, Hanping; Wang, Jing; Shao, Ning; Wu, Guanglong published a patent.Recommanded Product: 908267-63-0 The title of the patent was Preparation of heteroaryl compounds as casein kinase inhibitors. And the patent contained the following:

The title compounds with general formula I [wherein R1 = halogen; n = 0-2, X = independently C or N; R2 = absent or O; R3 = absent or CN; A = absent, a 4- to 7- membered (un)substituted cycloalkyl, heterocycloalkyl, a 5- to 6- membered (un)substituted heteroaryl, etc.; ring B = a 4- to 7-membered (un)substituted cycloalkyl, heterocycloalkyl, or a 5- to 6-membered (un)substituted heteroaryl, wherein up to 2 carbon atoms are replaced with a heteroatom selected from =N- or -O-] or pharmaceutically acceptable salts thereof were prepared novel casein kinase inhibitors. For example, compound II was prepared in a multi-step synthesis. Corresponding pharmaceutical compositions were also disclosed for the treatment of mood disorder, depression, bipolar disorder, solid tumor, blood cancer, lymphoma, breast cancer, melanoma, leukemia, liver cancer, and brain cancer. The experimental process involved the reaction of 4-Bromo-2-isopropylpyridine(cas: 908267-63-0).Recommanded Product: 908267-63-0

The Article related to preparation heteroaryl pyrazolopyrazine pyrimidine imidazopyrazine furopyridine, human casein kinase inhibitor treatment mood disorder cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 908267-63-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem